Milestone Pharmaceuticals (NASDAQ:MIST) CEO Joseph Oliveto Sells 34,523 Shares of Stock

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) CEO Joseph Oliveto sold 34,523 shares of the company’s stock in a transaction on Monday, January 26th. The shares were sold at an average price of $1.93, for a total value of $66,629.39. Following the completion of the sale, the chief executive officer owned 482,744 shares in the company, valued at $931,695.92. This trade represents a 6.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Joseph Oliveto also recently made the following trade(s):

• On Monday, December 15th, Joseph Oliveto sold 133,054 shares of Milestone Pharmaceuticals stock. The shares were sold at an average price of $2.32, for a total transaction of $308,685.28.
• On Thursday, January 8th, Joseph Oliveto sold 43,000 shares of Milestone Pharmaceuticals stock. The shares were sold at an average price of $2.25, for a total transaction of $96,750.00.
• On Wednesday, January 7th, Joseph Oliveto sold 500 shares of Milestone Pharmaceuticals stock. The shares were sold at an average price of $2.25, for a total value of $1,125.00.

Milestone Pharmaceuticals Stock Performance

Shares of NASDAQ:MIST opened at $1.94 on Thursday. The business has a fifty day moving average of $2.23 and a 200-day moving average of $1.96. The company has a debt-to-equity ratio of 2.74, a quick ratio of 8.24 and a current ratio of 8.24. Milestone Pharmaceuticals Inc. has a twelve month low of $0.63 and a twelve month high of $3.06. The firm has a market cap of $165.23 million, a PE ratio of -2.37 and a beta of 0.44.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.05. On average, equities research analysts predict that Milestone Pharmaceuticals Inc. will post -0.62 EPS for the current fiscal year.

Institutional Trading of Milestone Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. Simplify Asset Management Inc. increased its stake in Milestone Pharmaceuticals by 186.2% in the 3rd quarter. Simplify Asset Management Inc. now owns 2,832,974 shares of the company’s stock valued at $5,666,000 after buying an additional 1,842,974 shares during the last quarter. Valeo Financial Advisors LLC boosted its stake in shares of Milestone Pharmaceuticals by 553.5% during the 2nd quarter. Valeo Financial Advisors LLC now owns 130,699 shares of the company’s stock worth $254,000 after buying an additional 110,699 shares during the last quarter. Aptus Capital Advisors LLC bought a new position in shares of Milestone Pharmaceuticals in the 3rd quarter valued at about $420,000. Propel Bio Management LLC increased its position in shares of Milestone Pharmaceuticals by 186.1% in the third quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company’s stock valued at $10,250,000 after acquiring an additional 3,333,333 shares during the last quarter. Finally, Raymond James Financial Inc. increased its position in shares of Milestone Pharmaceuticals by 30.1% in the second quarter. Raymond James Financial Inc. now owns 43,235 shares of the company’s stock valued at $84,000 after acquiring an additional 10,000 shares during the last quarter. Institutional investors own 86.18% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Wells Fargo & Company boosted their target price on Milestone Pharmaceuticals from $4.00 to $8.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th. TD Cowen raised shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, December 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a report on Monday, December 29th. Wall Street Zen lowered shares of Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Finally, Zacks Research raised shares of Milestone Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Milestone Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.00.

Trending Headlines about Milestone Pharmaceuticals

Here are the key news stories impacting Milestone Pharmaceuticals this week:

• Positive Sentiment: Milestone launched CARDAMYST nasal spray for U.S. pharmacy availability — a commercial milestone that could begin to drive product revenue and awareness. Milestone Launches CARDAMYST Nasal Spray in U.S. Pharmacies
• Positive Sentiment: Analyst optimism rose after Zacks upgraded MIST from “Hold” to a “Strong Buy” (Zacks Rank #1), which may attract buyers and short‑term momentum flows. All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy
• Neutral Sentiment: Trading context: shares are trading below the 50‑day moving average and volume is below the stock’s average, which can mute a sustained bounce despite the product launch and upgrade.
• Negative Sentiment: CEO Joseph Oliveto completed sizeable stock sales: 133,054 shares on Dec. 15 at ~$2.32 and 34,523 shares on Jan. 26 at ~$1.93 — material reductions disclosed to the SEC that may worry investors about insider confidence or trigger selling pressure. SEC Form 4 – Joseph Oliveto
• Negative Sentiment: Other insiders (David Bharucha and Lorenz Muller) also sold large blocks on both Dec. 15 (~58k and ~53.6k shares respectively) and Jan. 26 (~12.2k and ~11.2k shares respectively), representing substantial percentage reductions in their holdings. These clustered insider sales intensify negative sentiment. SEC Form 4 – David Bharucha SEC Form 4 – Lorenz Muller
• Negative Sentiment: COO Jeffrey Nelson similarly sold significant shares on Dec. 15 and Jan. 26 (including ~58k on Dec. 15), cutting his stake materially — another factor pressuring sentiment. SEC Form 4 – Jeffrey Edward Nelson

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.